Analyzes British, Australian, and German health systems' policies on covering expensive end-of-life drugs while maintaining equity and efficiency, such as requiring evidence of comparative clinical and cost-effectiveness. Outlines challenges for the U.S.
Use this form to customize and generate the code you need to display this content in your own environment - no programming required. The feed will inherit more specific styles, like font face and font color, from your website.
Your code
Preview
